Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Cardiology
•
Preventive Cardiology
What is a reasonable way to treat statin-induced myalgia and what statin substitute would you consider using in the event the myalgia is not resolved?
Answer from: at Community Practice
Qunol co administration Vytorin - lower doses PCSK9
Comments
at Valley Heart Institute Of Doctors Medical Center
Opportunities with pcsk9 monoclonal antibodies or ...
11574
Sign in or Register to read more
21557
Related Questions
Should we be more cautious with the use of GLP 1 R agonist therapy in patients with Type 1 diabetes mellitus and obesity given the increased risk of cardiovascular disease with high body weight variability?
Is moderate-intensity statin plus ezetimibe just as effective as high-intensity statin monotherapy in preventing major cardiovascular events?
Is there a role of prophylactic aspirin in patients with incidental findings of aortic atherosclerosis but no history CAD or CVA?
Would you consider adding niacin to the lipid lowering regimen in statin-intolerant patients who cannot afford PCSK9i or bempedoic acid?
What is a reasonable approach to coronary calcification that is incidentally found on CT in a patient who does not have symptoms suggestive of angina?
Would it be reasonable to consider switching from a high intensity statin therapy to PCSK9 inhibitor vs. adding adjunct lipid lowering medications for a patient with known coronary artery calcifications, LDL in the mid-100 range pre-statin with worsening A1C levels?
Does oral semaglutide provide similar cardiovascular risk reduction benefits as injectable semaglutide?
Should CT coronary calcium score be avoided in dialysis patients in light of presumed high prevalence of CAC in this population?
How should we approach the recommendation of intermittent fasting for weight loss in patients with pre-existing cardiovascular conditions, given the observed association of increased CV mortality with eating durations of less than 8 hrs?
Is there a role for colchicine in the management of patients after a myocardial infarction given the conflicting results of the COLCOT trial, which found a significant reduction in subsequent cardiovascular events, and the CLEAR SYNERGY (OASIS-9) trial, which did not find a significant benefit?
Opportunities with pcsk9 monoclonal antibodies or ...